4/16
10:12 am
nams
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today [Seeking Alpha]
Low
Report
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today [Seeking Alpha]
4/8
08:00 am
nams
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
Low
Report
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
4/2
05:43 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
09:57 am
nams
Here's Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4 [Yahoo! Finance]
Medium
Report
Here's Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4 [Yahoo! Finance]
3/29
07:32 pm
nams
Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS) [Yahoo! Finance]
Low
Report
Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS) [Yahoo! Finance]
3/23
08:32 am
nams
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
Medium
Report
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
3/23
08:00 am
nams
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
Medium
Report
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
3/18
04:00 pm
nams
NewAmsterdam Pharma (NAMS) is now covered by Truist Financial Corporation. They set a "buy" rating and a $57.00 price target on the stock.
Medium
Report
NewAmsterdam Pharma (NAMS) is now covered by Truist Financial Corporation. They set a "buy" rating and a $57.00 price target on the stock.
3/6
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/25
08:00 am
nams
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
Medium
Report
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
2/23
06:23 am
nams
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering [Yahoo! Finance]
Low
Report
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering [Yahoo! Finance]
2/21
02:04 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by analysts at
Wall Str
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by analysts at
Wall Str
2/20
07:27 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
2/19
03:08 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
2/19
08:42 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/18
12:54 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $46.00 to $48.00. They now have a "buy" rating on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $46.00 to $48.00. They now have a "buy" rating on the stock.
2/18
07:00 am
nams
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
2/6
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4
08:00 am
nams
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
Low
Report
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit